James Demos
Nephrology · Old Bridge, NJNPI 1457353872
Payments from drug & device makers
Across 204 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$573
- Novo Nordisk$508
- AbbVie$380
- Pfizer$210
- GSK$183
- Exact Sciences$178
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$130%
- Food & beverage$3,137100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $573 |
| Novo Nordisk | 34 | $508 |
| AbbVie(2 entities) | 26 | $380 |
| Pfizer | 14 | $210 |
| GSK | 12 | $183 |
| Exact Sciences | 6 | $178 |
| Amgen | 10 | $158 |
| Johnson & Johnson | 10 | $155 |
| Amarin Pharma, Inc. | 10 | $142 |
| Boehringer Ingelheim | 9 | $131 |
| Lilly USA, LLC | 5 | $81 |
| Merck | 5 | $71 |
| Bayer | 3 | $63 |
| Abbott | 4 | $60 |
| Daiichi Sankyo Inc. | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Dynavax Technologies Corporation | 2 | $22 |
| Krystal Biotech Inc | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Novartis | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Medicure Pharma Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
How this compares
$3,151 in reported general payments places this provider in the 70th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $39,931 |
| JanuviaSitagliptin Phosphate | 31 | $38,131 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $31,520 |
| XareltoRivaroxaban | 11 | $17,354 |
| OzempicSemaglutide | 11 | $12,954 |
| TrulicityDulaglutide | 12 | $11,029 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $9,024 |
| Levothyroxine Sodium | 280 | $3,834 |
| Atorvastatin Calcium | 306 | $3,700 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,842 |
| Rosuvastatin Calcium | 73 | $2,542 |
| Esomeprazole Magnesium | 27 | $2,195 |
| Desloratadine | 13 | $2,189 |
| Metoprolol Succinate | 116 | $2,043 |
| FenofibrateFenofibrate Nanocrystallized | 28 | $1,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $71 | $69,65152 claims |
| PfizerEliquis | $210 | $39,93145 claims |
| Johnson & JohnsonXarelto | $155 | $17,35411 claims |
| Novo NordiskOzempic | $508 | $12,95411 claims |
| Lilly USA, LLCTrulicity | $81 | $11,02912 claims |
| AbbVieSynthroid | $380 | $1,46918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Old Bridge
- Danny HaddadJersey City$1.7M
- Anup PatelWest Orange$1M
- Joshua KaplanNewark$509K
- Lawrence ByrdLivingston$338K
- Devang LodhaviaVoorhees$321K
- Jeffrey FeldmanUnion$315K
- Kenneth LissEatontown$271K
- Narender GoelJersey City$181K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.